SCHEMBL2822006

SCHEMBL2822006

Cc1cccc(/C=C/c2nc3ccccn3c(=O)c2Br)c1OC1CCCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.34
KDM4E B2RXH2 3/20 0.33
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 4/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE7A Q13946 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RXFP1 Q9HBX9 2/20 0.33
KCNK3 O14649 1/20 0.33
KCNK9 Q9NPC2 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2822010 1.00 CNR2 (0.34) CNR2KDM4EPOLBMAPTTDP1
SCHEMBL2818958 0.89 LMNA (0.39) CNR2POLBMAPTKMT2AALDH1A1
SCHEMBL2818956 0.89 LMNA (0.39) CNR2POLBMAPTKMT2AALDH1A1
SCHEMBL2821522 0.82 KCNK3 (0.38) KDM4EPOLBMAPTTDP1ALDH1A1
SCHEMBL2820673 0.81 ALDH1A1 (0.40) KDM4EPOLBMAPTMEN1KMT2A
SCHEMBL2817948 0.77 LMNA (0.38) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL2817945 0.77 LMNA (0.38) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL2819041 0.76 LMNA (0.39) POLBMAPTKMT2AALDH1A1NPC1
SCHEMBL2819037 0.76 LMNA (0.39) POLBMAPTKMT2AALDH1A1NPC1
SCHEMBL2821810 0.76 KDM4E (0.39) KDM4EMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators TRPV3, TRPV1, TRPV5 CNR2 93/4885KDM4E 1749/4885POLB 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.